The
Female Health Company (FHCO) is a global manufacturer and distributor
of the FC2 Female Condom, a barrier method of contraception that is
designed to provide protection against sexually transmitted infections
and unintended pregnancies. The company is headquartered in Chicago,
Illinois.
Female Health Company had a market capitalization of
approximately $31 million. The company's total revenue for the fiscal
year 2020 was $13.2 million, a decrease from $17.2 million in the
previous year. Net loss for the same period was $5.5 million, an
improvement from a net loss of $7.1 million in the previous year.
The FC2 Female Condom is distributed in over 140 countries
worldwide, and is recognized as an important tool for promoting sexual
health and reducing the spread of sexually transmitted infections. The
company is committed to increasing awareness and access to the FC2
Female Condom, and has partnered with a range of organizations to
promote sexual health and empowerment.
The company faces
competition from other manufacturers of barrier methods of
contraception, and is subject to various risks, including regulatory
risks and changes in market conditions. However, the Female Health
Company's focus on promoting sexual health and empowerment, along with
its global distribution network, should position it well for continued
success in the future.
The Female Health Company's stock is
listed on the NASDAQ stock exchange under the ticker symbol FHCO.
Investors should carefully consider their investment objectives, risk
tolerance, and other factors before investing in the Female Health
Company or any other healthca
|
